SERA

Sera Prognostics, Inc. ( SERA ) Q3 2026 Earnings Call November 4, 2026 5:00 PM EST Company Participants Jennifer Zibuda - Head of Investor Relations Evguenia Lindgardt - President, CEO & Director Lee Anderson - Chief Commercial Officer Tiffany Inglis - Chief Medical Officer Scott Gleason - CFO & Treasurer Conference Call Participants William Bonello - Craig-Hallum Capital Group LLC, Research Division William Ruby - TD Cowen, Research Division Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the Sera Prognostics Third Quarter 2026 Financial Results. [Operator Instructions] I would like to remind everyone that this call is being recorded on Wednesday, November 4, 2026.

Sera Prognostics NASDAQ: SERA reported a sharp increase in use of its PreTRM preterm birth risk test in the third quarter of 2026, as the company expanded its commercial efforts in Illinois and Florida following Medicaid coverage decisions in both states.

Company Drives Significant Increases in Test Volume and Ordering Providers with Florida Becoming Second Medicaid State Covering Test PreTRM® test volume increases 54% sequentially and approximately five-fold from 1Q26 Ordering healthcare providers increase 34% sequentially and approximately three-fold from 1Q26 Florida provides Medicaid coverage for PreTRM® with established fee schedule pricing PreTRM® mentioned in European Association for Perinatal Medicine guidelines Started CE Mark submission for PreTRM® Global in Europe Company scales commercial organization to support anticipated test volume ramp in fiscal year 2027 SALT LAKE CITY, Nov. 4, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter ended September 30, 2026. "The third quarter marked an important step forward as we continued our transition from evidence generation to commercial execution," said Zhenya Lindgardt, President and Chief Executive Officer of Sera Prognostics.

SALT LAKE CITY, Oct. 21, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report its third quarter fiscal year 2026 financial results on Wednesday, November 4, 2026, after market close. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.

Dr. Thaïs Aliabadi, a board-certified OB-GYN and co-host of the SHE MD podcast, makes the case that preterm birth risk is personal, knowable between weeks 18 and 21 of pregnancy, and worth a direct conversation with your doctor. She points to a simple blood test, the PreTRM® Test from Sera Prognostics, and PRIME trial results showing early, low-cost intervention can cut the earliest preterm births by more than half.

SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced today that Scott Gleason has been appointed Chief Financial Officer (CFO), effective August 31, 2026. Mr. Gleason brings more than 25 years of healthcare, diagnostics, and capital markets experience to Sera.

Sera Prognostics NASDAQ: SERA reported modest second-quarter revenue while outlining progress in payer engagement, Illinois Medicaid policy, clinical evidence and European regulatory preparations for its PreTRM Test-guided care platform.

Sera Prognostics, Inc. (SERA) Q2 2026 Earnings Call Transcript

SALT LAKE CITY, Aug. 12, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter ended June 30, 2026. Key Second Quarter and Recent Highlights: Advanced Commercial Adoption Strategy with Fourth Partnership Program Launch: In August 2026, we launched fourth partnership program, expanding implementation of PreTRM® Test-guided care through a state-based initiative with a national payer.

SALT LAKE CITY, July 29, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report second quarter fiscal year 2026 financial results on Wednesday August 12, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.